Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PLEC | Q15149 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21219645 | 0.85 | SIRT6 (0.46) | GSK3AGSK3BGAASIRT6SCN2A | |
| SCHEMBL9187712 | 0.81 | GSK3A (0.56) | GSK3AGSK3BGAASIRT6SCN2A | |
| SCHEMBL5328812 | 0.78 | HPN (0.58) | GSK3AGSK3BGAASCN2AMAPT | |
| SCHEMBL11768509 | 0.77 | MAPT (0.57) | GSK3AGSK3BGAASIRT6SCN2A | |
| SCHEMBL25989164 | 0.74 | CA12 (0.53) | GSK3AGSK3BGAASCN2AMAPT | |
| SCHEMBL11078565 | 0.74 | TDP1 (0.59) | MAPTPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL28604247 | 0.73 | HSD17B10 (0.56) | GSK3AGSK3BSIRT6SCN2AADRB1 | |
| SCHEMBL12490798 | 0.73 | APOBEC3G (0.50) | MAPTPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL22567 | 0.72 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1MAPK1HSD17B10 | |
| SCHEMBL27909482 | 0.72 | ALDH1A1 (0.72) | MEN1KMT2AALDH1A1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12607640-B2 | Mass spectrometry of steroidal compounds in multiplex samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2026-04-21 | — | — | US | claimed |
| US-20250216404-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVEST LLC (US) | 2025-07-03 | — | — | US | claimed |
| US-20230375575-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2023-11-23 | — | — | US | claimed |
| US-11808773-B2 | Mass spectrometry of steroidal compounds in multiplexed patient samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2023-11-07 | — | — | US | claimed |
| US-20210349109-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2021-11-11 | — | — | US | claimed |
| US-10955424-B2 | Mass spectrometry of steroidal compounds in multiplexed patient samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2021-03-23 | — | — | US | claimed |
| EP-3693734-A2 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | Quest Diagnostics Investments Incorporated (US) | 2020-08-12 | — | — | EP | claimed |
| CN-107607662-B | Mass spectrometry of steroids in multiplex samples | 奎斯特诊断投资公司 | 2020-05-08 | — | — | CN | claimed |
| EP-2510347-B1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | QUEST DIAGNOSTICS INVEST INC (US) | 2019-03-20 | — | — | EP | claimed |
| US-20170261523-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2017-09-14 | — | — | US | claimed |
| US-20160061848-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2016-03-03 | — | — | US | claimed |
| US-9034653-B2 | Mass spectrometry of steroidal compounds in multiplexed patient samples | QUEST DIAGNOSTICS INVESTMENTS INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20140051176-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2014-02-20 | — | — | US | claimed |
| US-20130137185-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2013-05-30 | — | — | US | claimed |
| US-20110240840-A1 | MASS SPECTROMETRIC DETERMINATION OF COOKSON-DERIVATIZED, NON-METABOLIZED VITAMIN D | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-10-06 | — | — | US | claimed |
| US-20110226944-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-09-22 | — | — | US | claimed |
| US-7977117-B2 | Vitamin D metabolite determination utilizing mass spectrometry following derivatization | Quest Diagnostics Investments Incorprated (US) | 2011-07-12 | — | — | US | claimed |
| US-20110133068-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS LLC | 2011-06-09 | — | — | US | claimed |
| WO-2011068707-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2011-06-09 | — | — | WO | claimed |
| WO-1990000897-A1 | METHOD FOR THE CONTROL OF HYPERLIPIDEMIA | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1990-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12607640-B2 | Mass spectrometry of steroidal compounds in multiplex samples | CYP24A1, CYP2R1, SRD5A1 | GSK3A 719/4885GSK3B 788/4885GAA 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.